

Pembrolizumab KEYNOTE-048

## PRELIMINARY SCORE

### CURATIVE



### NON-CURATIVE



## ADJUSTMENTS

### Quality of life



No QoL benefit



### Serious and disabling adverse effects



### Other adjustments



Pembrolizumab KEYNOTE-048

## FINAL SCORE

### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

### NON-CURATIVE



Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

### INFORMATION

Tumour type: Head and neck cancer

Therapeutic Indication: In combination with platinum and 5-fluorouracil (5-FU) chemotherapy is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a CPS  $\geq 1$

Experimental Arm: Pembrolizumab + Cisplatin or carboplatin/5-FU

Control Arm: Cisplatin or carboplatin/5-FU/cetuximab



